Health Canada

Health Canada is the federal department responsible for drug regulation in Canada, and its decisions define ibogaine's legal position there. Ibogaine is not an approved therapeutic product in Canada, and the department's regulatory framework governs whether it can be imported, sold, or administered, including the pathways through which a sponsor could seek authorization for a clinical trial or an individual could seek access to an unapproved drug. The department has issued public advisories about ibogaine, including warnings about serious cardiac risks and the sale of unauthorized health products containing it, and those advisories are cited in discussion of ibogaine's safety profile and legal status. Canada also hosts organizations active in the ibogaine field, so the department's position affects advocacy, harm-reduction publishing and clinical proposals originating in the country. The department does not provide treatment or fund ibogaine clinics. Its documented impact on the space is regulatory and informational: it sets the conditions under which lawful research or supervised administration could take place in Canada, and its safety communications form part of the public record that this wiki cites when describing cardiac and other risks associated with the compound.